anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic kidney disease (CKD) is associated with 5% of all pediatric inpatient venous thromboembolism (VTE) occurrences, but rates of occurrence are likely underreported in current literature. VTE is associated with a 2-fold increase in mortality, and exponentially higher rates of healthcare expenditure. Because VTE is a low-incidence but high-impact complication of CKD, evaluating those at risk presents a unique challenge. The underlying pathophysiology of thrombosis in CKD is poorly understood, but likely involves changes across the hemostatic and fibrinolytic systems. Standard laboratory tests provide a poor representation of in-vivo clot formation, particularly in the complex hemostatic environment of CKD, as these tests undergo centrifugation and much of the cellular debris known to contribute to clot formation is lost. Viscoelastic assays are a reemerging tool that provide a qualitative measure of each hemostatic milestone, from clot formation through degradation, in whole-blood; thereby preserving the cellular debris and additional factors that contribute to clot formation in-vivo.

The purpose of this study is to evaluate the utility of Thrombelastography vs conventional clotting tests to predict onset of hypercoagulability and the relationship to the stage of pediatric Chronic Kidney Disease (CKD). The investigators hypothesize that as kidney function deteriorates, a more pronounced prothrombotic profile is expected to emerge according to TEG and conventional clotting tests. This will be demonstrated by an overall increase in measured values across the coagulation portion of the TEG and a decrease in the measured fibrinolysis. According to conventional clotting tests, it is expected to find increased levels of Factor VIII antigen, Fibrinogen, vWF, Protein C/S, and D-dimer. Depending upon an individual's degree of proteinuria, levels of Antithrombin would be expected to decrease as it is lost in the urine. This urinary loss of Antithrombin would also contribute to an overall prothrombotic profile.

This cross-sectional pilot study will enroll 30 participants between the ages of 6 months and 17 years who have been previously diagnosed with CKD stages 3, 4, or 5. Enrollment will occur during a routine clinic visit wherein the participant was also previously scheduled to receive venipuncture for ongoing monitoring of labs. Study specific lab values, in addition to routine lab values of interest and pertinent past medical history, will be extracted from the EMR.
ASA I-II, aged 19-65 years undergoing general anesthesia with DLT for lung wedge resection were enrolled in this study.After completing the surgery, the propofol infusion was stopped, and effect-site concentration of remifentanil was titrated to predetermined concentration ( initial concentration being 1.5ng/ml for the first patient).The predetermined concentration was maintained at least 10 min throughout emergence for the effect site concentration and plasma concentration can be expected stable. The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
The trial will be conducted in a manner of simon two-stage design with Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with Diffuse Large B Cell Lymphoma(DLBCL). Only when the expected reaction rate is achieved the 30 patients left can be recruited.
The present invention relates to health protection cream with dual functions of oral administration and external application and a preparation method thereof. The health protection cream is prepared from the raw materials by the following weight percentage: 28 to 32 % of vegetable oil, 0.05 to 0.15 % of puerarin, 0.2 to 0.35 % of tea polyphenols, 1.2 to 1.8 % of sobitan monopa1 mitate, 1.5 to 2.0 % of sobitan monopa1 mitate of polyoxyethylene, 2 to 5 % of sodium alginate, 8 to 15 % of glycerol, 0.3 to 2 % of sodium benzoate, 0.1 to 0.3 % propyl p-hydroxybenzoate and water as the rest. The preparation method comprises the steps: preparing oil phase solution, preparing water phase solution, emulsifying, homogenizing and packaging. The health protection cream of the present invention can be eaten as a health protection preventing product, and can be externally used as a skin protection product. The dual effect is achieved, the forbidden zone that cosmetics can not be eaten and the external application of a health protection product is ineffective is broken through, and the use is convenient. The health protection cream is especially suitable for people in the subhealth state for emergency requirements on outing tours or special occasions.
The potential for secondary stroke prevention, which can significantly reduce the risk of recurrent strokes by almost 90%, underscores its critical importance. N-butylphthalide (NBP) has emerged as a promising treatment for acute cerebral ischemia, yet its efficacy for secondary stroke prevention is hindered by inadequate pharmacokinetic properties. This study, driven by a comprehensive structural analysis, the iterative process of structure optimization culminated in the identification of compound B4, which demonstrated exceptional neuroprotective efficacy and remarkable oral exposure and oral bioavailability. Notably, in an in vivo transient middle cerebral artery occlusion (tMCAO) model, B4 substantially attenuated infarct volumes, surpassing the effectiveness of NBP. While oral treatment with B4 exhibited stronger prevention potency than NBP in photothrombotic (PT) model. In summary, compound B4, with its impressive oral bioavailability and potent neuroprotective effects, offers promise for both acute ischemic stroke treatment and secondary stroke prevention.
NEW MATERIAL:A compound expressed by formula I (R1 is H, 1-3C alkyl, etc.; R2 is 1-3C alkyl or R1 and R2 link to represent pyrrolidine, piperidine, thiazoline, etc.; n is 1-3) or salts thereof. EXAMPLE:1-(3-Phenyl-5-isoxazolyl)-2-morpholinoethylpiperidine fumarate. USE:A central muscle relaxant useful for treating spastic paralysis caused by myotonic conditions, cerebrovascular disorder, etc., due to herniation of intervertebral discs, etc., and excellent in central muscle relaxing action with high safety. PREPARATION:A 3-phenyl-5-chloro-isoxazole expressed by formula II is initially reacted with a piperidine compound expressed by formula III in an amount of 1-10equiv. based on the above-mentioned compound to provide a compound expressed by formula IV, which is then reacted with 1-5equiv. compound expressed by the formula ClSO2R (R is methyl or toluyl). The resultant compound expressed by formula V is subsequently reacted with 1-5equiv. compound expressed by formula VI.
Preeclampsia is a complex pregnancy-related hypertensive disorder which poses significant risks for both maternal and fetal health. Preeclampsia affects 5-8% of pregnancies in the United States, causing a significant public health and economic burden. Despite extensive research, the etiology and pathogenesis of preeclampsia remain elusive, but have been correlated with maternal conditions such as obesity. In recent decades, the incidence of preeclampsia increased along with the prevalence of obesity among women of reproductive age. Maternal obesity has been shown to negatively affect pregnancy in almost all aspects. However, the precise mechanisms by which obesity influences preeclampsia are unclear. Ankyrin repeat and SOCS Box Containing protein 4 (ASB4) is an E3 ubiquitin ligase that can promote the degradation of a wide range of target proteins. ASB4-null mice display a full spectrum of preeclampsia-like phenotypes during pregnancy including hypertension, proteinuria, and decreased litter size. Furthermore, maternal obesity induced by a high-fat diet aggravates preeclampsia-like phenotypes in pregnant mice lacking ASB4. Variants in the ASB4 gene have been associated with obesity in humans, and a functional connection between the ASB4 gene and obesity has been established in mice. This review discusses the connections between preeclampsia, obesity, and ASB4.
NEW MATERIAL:Epithelial growth inhibitor (EGI for short) (molecular weight: about 27,000; being deactivated by reduction; consisting of two subunits). USE:A carcinostatic agent inhibiting multiplication of human squamous cell carcinoma cell. PREPARATION:Human blood is centrifuged, erythrocyte is precipitated and supernatant liquid is collected. The supernatant liquid is centrifuged to give blood platelet precipitate, which is suspended in PBS, centrifuged again to give blood platelet precipitate. The precipitate is suspended in acidic ethanol having a composition shown by table, treated by a homogenizer, the prepared homogeneous solution is centrifuged, the precipitate is dried in vacuum, dissolved in 1M acetic acid and the prepared solution is used as an extracted solution of blood platelet. The extracted solution is sent to equilibrated TOYOPAL HW50 column, developed with 1M acetic acid and treated by chromatography to elute a large amount of EGI of fraction number 23-28. The EGI is collected and purified to give almost pure EGI.
<P>PROBLEM TO BE SOLVED: To defense and treat Staphylococcus epidermidis infection.  <P>SOLUTION: The process is disclosed for culturing clinical Staphylococcus epiddermids cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive immunization against S. epidermidis infection and to produce a hyperimmune immunoglobulin or antibodies for treatment of S. epidermidis infection.  <P>COPYRIGHT: (C)2004,JPO
This study was a single-center, observational, prospective cohort study. The study lasted for 3 months, from 2024.11 to 2025.02.It is planned to enroll 40 subjects, divided into 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients. No randomization or any protocol-driven treatment will be performed or provided to subjects during the course of the study. Treatment decisions and selection of treatment options are left to the discretion of the treating physician, if clinically appropriate. All recipients will be followed for aGVHD evaluation,overall survival(OS) ,disease-free survival (DFS). aGVHD were graded according to published guidelines. All recipients will be monitored every month until the study is completed.
FIELD: medicine. SUBSTANCE: invention relates to dermatological composition for local using that provides lose weight. Composition has the first dispersion of lipid vesicules that are able to penetrate into deep layers of skin and containing at least one an active agent taken from lipolytic agents, and the second dispersion of lipid vesicules that are able to penetrate into surface layers of skin and containing at least one an active agent taken from agents that are able to effect on skin surface. Invention provides making the composition for local using for lose weight and development of the "soft" method of lose weight. EFFECT: enhanced effectiveness of method and composition. 17 cl, 3 ex, 2 tbl
BACKGROUND: The role of gasdermin D (GSDMD) in bloodstream infection (BSI) diagnosis is unknown.
METHODS: Serum GSDMD levels were measured in patients with BSI. Endothelial cells and peripheral blood mononuclear cells were isolated and infected with bacteria/fungi, and intracellular/extracellular GSDMD concentrations were measured. An animal model was established to investigate the association between serum GSDMD levels and BSI incidence or progression.
RESULTS: Receiver operating characteristic curve analysis indicated that GSDMD could be a potential early diagnostic biomarker for BSI (area under the curve [AUC], .9885). Combining GSDMD with procalcitonin improved the differential diagnosis of gram-positive and gram-negative bacteria (AUC, 0.6699; 66.15% specificity) and early diagnosis of gram-positive bacteria (98.46% sensitivity), while procalcitonin was not significantly elevated. The combined GSDMD and (1-3)-β-D glucan test (G test) had higher sensitivity (AUC, 0.7174) for differential diagnosis of bacterial and fungal infections and early detection of fungal infections (98.44% sensitivity). In vitro and in vivo experiments confirmed that GSDMD levels increased significantly within 2 hours, peaked at 16 hours, and exhibited a time-dependent upward trend.
CONCLUSIONS: Serum GSDMD, alone or combined with other biomarkers, has potential for early diagnosis and differential diagnosis of BSI caused by various pathogens. This finding offers a new strategy for early detection and treatment of BSI.
The invention discloses a double-layer cleansing lotion and a preparation method thereof. The double-layer cleansing lotion comprises a water-phase layer and an oil-phase layer. The water-phase layer comprises water soluble preservatives, water soluble grease, inorganic salt electrolyte, moisturizing agent and water. The oil-phase layer comprises water-insoluble grease, oil soluble preservatives and oil soluble pigment. The preparation method includes: sequentially adding water soluble preservatives, water soluble grease, inorganic salt electrolyte and moisturizing agent into water, well mixing to obtain water-phase layer components, sequentially adding oil soluble preservatives and oil soluble pigment in water-insoluble grease, well mixing to obtain oil-phase layer components, and mixing the water-phase layer components and the oil-phase layer components to obtain the double-layer cleansing lotion. During use, the double-layer cleansing lotion can be emulsified by shaking to form emulsion, and instant deemulsification occurs to form double-layer structure with clearly-separated oil and water when the double-layer cleansing lotion stands still. The double-layer cleansing lotion is mild in cleansing, instant in emulsification, fast in deemulsification, clear in boundary and the like.
The present invention provides a drug formulation comprising a hydrophobic drug, an oil phase and a surfactant and a dosage form. The drug formulation works to increase the bioavailability of hydrophobic drugs delivered to the gastro-intestinal tract ('GI tract') of a desired subject. The drug formulation of the present invention is formulated as a self-emuslifying nanosuspension, which forms an emulsion in-situ upon introduction to an aqueous environment. The dosage form of the present invention may be formed using various different materials and may be configured to deliver the drug formulation of the present invention to the GI tract of a subject using any desired mechanism. A controlled release dosage form according to the present invention may be designed to deliver the drug formulation of the present invention at a desired rate over a desired period of time. If designed as a controlled release dosage form, the dosage form of the present invention may be an osmotic dosage form.
After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid.
FIELD: biotechnology, molecular biology. SUBSTANCE: invention can be used for the development of functionally active tyrosine-specific protein kinase chimeras. The constructed chimeric receptor comprises b-noncellular moiety that recognize specifically cell-target or infectious agent-target, transmembrane domain and intracellular moiety representing human or swine protein-tyrosine kinase Syk, or protein-tyrosine kinase ZAP-70, or derivative of CD28. DNA encoding chimeric receptor is cloned into expressive cowpox virus vector that is used for transfection of mammalian cells. Transfected cells expressing two or three different chimeric receptors comprising, respectively, intracellular moiety of protein-tyrosne kinase Syk and CD28 or intracellular moiety of ZAP-70, Sre and CD28 are administrated to mammal in effective dose for destroying cell-target or infectious agent-target. Invention provides the development of agents that are able to target therapeutic cells for specific recognition and destroying cell-target or infectious agent-target. EFFECT: improved destroying method, valuable biological properties. 32 cl, 19 dwg
PROBLEM TO BE SOLVED: To obtain the subject composition having a wetting effect for reducing itchiness and an effect for reducing allergy, and imparting a gross and a conditioning effect to a hair by containing an (aqueous) alcohol extract of a seed or a fruit of a specific plant as an active component. SOLUTION: This composition for treating a hair or a scalp, uses an alcohol or an aqueous alcohol extract of a seed or a fruit of a plant selected from a group of a rye, a rice, a barley, a corn, a millet, and a spelt. The blending amount of the plant extract (based on a dry content) is 0.05-10wt.% based on the total composition. As a solvent, water/polyhydric alcohol, especially water/ propylene glycol is preferable. The composition is also allowed to contain another plant extract of a bamboo meristem, a bamboo pitch an/or a licorice root. Also, the composition is allowed to contain a hydroxycarboxylic acid to increase an activity thereof. The pH of the extract is preferably in an acidic range, especially and approximately 4-5.5.
PURPOSE:To produce the titled polysaccharide having hypoglycemic activity, in a short time, in large guantities, independent of the weather, by carrying out the tissue culture of Panax ginseng belonging to Aradiaceae Family and extracting a specific component from the cultured product. CONSTITUTION:A part of the tissue of Panax ginseng is cut off, sterilized, cut in round slices of 5-10mm thick and cultured stationary on Murashige- Skoog medium added with 0.1-10ppm vegetable hormone (e.g. indoleacetic acid) at 20-25 deg.C to effect the induction of a callus. The obtained white callus is cultured in a medium obtained by adding 0.1-5wt% glucose and <=5ppm auxins to the above Skoog medium. The obtained callus is extracted with an aqueous organic solvent to obtain a mixture of panaxanes A-E, which is fractionated by the combination of anion exchange resin treatment and molecular weight fractionation process. The objective panaxane A having the characteristics of the Table can be separated from the mixture.
The invention discloses a scar repairing paste. The scar repairing paste comprises a lining layer, a viscous polymer layer and a separating layer which are bonded in sequence. The viscous polymer layer comprises viscous polymer, a lipidosome penetration promoting agent and scar removing active components. The weight ratio of the viscous polymer, the lipidosome penetration promoting agent and the scar removing active components is 150 to 200 parts of the viscous polymer, 70 to 90 parts of the lipidosome penetration promoting agent and 30 to 50 parts of scar removing active components. The viscous polymer is composed of polyacylate pressure-sensitive adhesive and hydroxyethyl cellulose. The weight ratio of the polyacylate pressure-sensitive adhesive and the hydroxyethyl cellulose is 100 to 120 parts of the polyacylate pressure-sensitive adhesive and 30 to 40 parts of the hydroxyethyl cellulose. The scar repairing paste has the advantages that good adhesiveness and caking property can be maintained under the condition of moisturizing and sweating, at the same time, good hydrophilcity and lipophilicity are achieved, penetrating the skin is more facilitated for medicine, the medicine absorption is quick, the adhesivity is good, a higher rate that the medicine penetrates through the skin can be obtained, and the therapeutic effect is good.
BACKGROUND: Individuals with wrist osteoarthritis (OA) can suffer from pain, muscular weakness, and impaired motion of the wrist, which can reduce the quality of life. While there is strong evidence that all patients with OA should receive first-line treatment with education and exercises, this approach has not yet been proposed for individuals with wrist OA. Therefore, this trial aimed to evaluate the effectiveness of a first line neuromuscular joint-protective exercise therapy program compared to a training program with range of motion (ROM) exercises in patients with wrist OA.
METHODS: In this randomized controlled trial (RCT), 48 patients with symptomatic and radiographically confirmed wrist OA were randomly allocated to a 12-week self-management program with either a neuromuscular joint-protective exercise therapy program (intervention group) or a training program with ROM exercises only (control group). Our primary outcome measure was the Patient-Rated Wrist Evaluation (PRWE) with secondary outcome measures of grip strength, range of wrist motion, the Numerical Pain Rating, Scale (NPRS), the Disabilities of the Arm, Shoulder, and Hand (DASH) and the Generalized Self-Efficacy Scale (GSES). The outcome measures were evaluated by a blinded assessor at baseline and 12 weeks. Between-groups differences were analyzed using the Mann-Whitney U test and within-group differences were analyzed with the Wilcoxon signed-rank test.
RESULTS: A total of 41 participants were analyzed at 12 weeks. There were no significant differences in PRWE between the groups at 12 weeks (p = 0.27). However, DASH improved significantly in the intervention group compared to the control group (p = 0.02) and NPRS on load within the intervention group (p = 0.006). The difference in DASH should be interpreted with caution since it could be due to a non-significant increase (worsening) from baseline in the control group in combination with a non-significant decrease (improvement) in the intervention group.
CONCLUSIONS: This RCT showed that the novel neuromuscular joint-protective exercise therapy program was not superior in reducing pain and improving function compared to a training program with ROM exercises at 12 weeks. Future research is warranted to evaluate the effectiveness of forthcoming exercise therapy treatment programs for patients with wrist OA.
TRIAL REGISTRATION: ClinicalTrials.gov, NCT05367817. Retrospectively registered on 10/05/2022. https://clinicaltrials.gov .
The present disclosure refers to a synergistic blend of Konjac powder and Xantnan gum that is included, as a natural suspending agent, in oral pharmaceutical suspensions. Oral pharmaceutical suspensions comprising the synergistic blend are aqueous solutions. The synergistic blend, used as a suspension agent to suspend suitable active pharmaceutical ingredients (APIs), improves the stability of oral pharmaceutical suspensions, and helps in the formation of a thermo-reversible gel and shear thinning necessary to keep APIs suspended within oral pharmaceutical suspensions. The synergistic blend of Konjac powder and Xanthan gum has unique anti-flocculation properties, which improve the homogeneity of the oral pharmaceutical suspensions. Additionally, the blend provides a better texture and mouth feel. Oral pharmaceutical suspensions, comprising the synergstic blend, include a vehicle, such as water, as well as different components, such as, for example APIs, preservatives, sweeteners, flavoring agents, and pH regulators or buffers, among others.